The present disclosure provides an A adenosine receptor (AAR) ligand for the treatment of sexual dysfunction. In some embodiments the AAR ligand is selected from an AAR agonist and AAR allosteric enhancer. The present disclosure also provides a method a method and pharmaceutical composition for treating a sexual dysfunction the method comprises administering to a subject having the sexual dysfunction an amount of an A adenosine receptor (AAR) ligand. In some embodiments the AAR ligand is an AAR agonist and more specifically IB MECA.